Biosimilar Launch Notification: Celltrion Claims Loophole In Remicade Suit
This article was originally published in The Pink Sheet Daily
Executive Summary
Celltrion contends that since it provided its infliximab biosimilar application to Janssen it doesn’t have to wait until FDA approval to provide 180-day notice of commercial launch.